Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors PARIS, June 13, 2022 — Mnemo Therapeutics, a biotechnology company developing …
Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors PARIS, June 13, 2022 — Mnemo Therapeutics, a biotechnology company developing …